Plain-English translation of NCT07807163 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medicine called combined with an immunotherapy drug called pembrolizumab to treat advanced or recurrent head and neck cancer. The medication works by targeting two proteins that help cancer grow and spread. Researchers want to find the best way to dose this medication—whether giving it every week works better than giving it every three weeks after an initial loading phase.
Head and neck cancer that has spread or come back after treatment is very difficult to treat, and existing options don't work well for everyone. This trial is exploring a new combination approach that targets cancer in two different ways at once, which researchers hope will be more effective.
You likely qualify if…
You likely don't qualify if…
All participants start with a 12-week loading phase, receiving the medication by infusion once a week plus immunotherapy every three weeks. After 12 weeks, if your cancer hasn't progressed, you'll be randomly assigned to continue either the weekly schedule or switch to a three-week schedule for the maintenance phase. You'll have regular visits for infusions, blood work, and scans to monitor how well the treatment is working and watch for side effects.
AI-generated summary from trial data · Sep 16, 2026 · Not medical advice
United States